MBF 132
Alternative Names: MBF-132Latest Information Update: 28 Sep 2024
At a glance
- Originator Medibiofarma
- Class Antifibrotics; Antineoplastics
- Mechanism of Action HDAC8 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer; Fibrosis
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for research development in Cancer in Spain
- 28 Sep 2024 No recent reports of development identified for research development in Fibrosis in Spain